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Intermediate phenotypes in schizophrenia:
a selective review
Gilbert A. Preston, MD; Daniel R.Weinberger, MD
tudies aiming to identify genes of susceptibility
for schizophrenia and other complex psychiatric disorders
are faced with the confounds of subjective clinical criteria,
commonly occurring phenocopies, significant between-
subject variability of candidate traits,and the likelihood of
allelic and locus heterogeneity that defines the genetics of
other complex human brain and somatic disorders.
1-10A
single genotype,for example,may be represented by an
array of psychiatric phenotypes;conversely,phenotype per
se most likely represents a variable number of interactions
between genotypes,epigenetic factors,and the environ-
ment.Additionally,research aimed at identification of the
molecular origins of schizophrenia must also deal with the
complex nature of the human brain.Unlike organs with a
few common cellular phenotypes,transcriptomes,and pro-
teomes, individual neurons are often distinct from one
another in all of these respects,and in aspects of local and
regional micro- and macrocircuitry;hence,human brain
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Studies aiming to identify susceptibility genes for schizophrenia and other complex psychiatric disorders are faced with
the confounds of subjective clinical criteria, commonly occurring phenocopies, significant between-subject variability
of candidate traits, and the likelihood of allelic and locus heterogeneity that has been shown to define the genetics of
other complex human brain and somatic disorders. Additionally, research aimed at identification of the molecular ori-
gins of schizophrenia must also deal with the confounding nature of the human brain. Unlike organs with a few com-
mon cellular phenotypes, transcriptomes, and proteomes, individual neurons are often distinct from one another in all
of these respects. In this review, we present recent work testing the assumption that studies of genetic susceptibility in
complex polygenic disorders such as schizophrenia might be enhanced by the identification of intermediate phenotypes
related to more fundamental aspects of brain development and function. Progress in the identification of meaningful
intermediate phenotypes in schizophrenia has been made possible by the advent of newer methods in cognitive neuro-
science and neuroimaging, and the use of combined multimodal techniques.  
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function reflects dynamic relationships between multiple
factors that modulate behavior and phenotype.
Genes only encode for molecules,not specific manifesta-
tions of psychopathology.The path from genetic variation
to variation in cell biology to manifest behavior must pass
through intermediate steps involving neural circuits and
systems.A brief summary of the complexity of genetic cau-
sation of psychiatric disorders will be detailed in this
review.We also discuss the idea that studies of genetic sus-
ceptibility in complex polygenic disorders such as schizo-
phrenia might be enhanced by the identification of inter-
mediate phenotypes,
11-13 and we present evidence derived
from more than a century-worth of clinical,epidemiolog-
ical,molecular genetic,and clinical neuroscience investi-
gations in support of the view of cognitive impairment as
a core clinical feature of schizophrenia.Most importantly,
evidence of heritability of specific impairments discussed
here may serve to further empower the search for genes
of risk.Necessarily,we shall not discuss all the potential
intermediate phenotypes,such as eye-tracking for exam-
ple,which have been recently reviewed in depth.
14
Definitions
An  intermediate phenotype (often referred to as an
endophenotype) is a quantitative biological trait that is
reliable and reasonably heritable,ie,shows greater preva-
lence in unaffected relatives of patients than in the general
population.A complex disorder arises from a polygenic
matrix whose individual components each confer only a
small portion of total risk,in contrast to a monogenic or
mendelian disorder.If a candidate intermediate phenotype
is to provide meaningful information about a disorder,it
should be associated with variant alleles that distinguish
patients and their unaffected siblings from healthy con-
trols on quantitative measures.The most useful interme-
diate phenotype candidates will also be functionally asso-
ciated with aspects of the core clinical deficits of the
disorder.The intensive search for such candidates is based
in part on a reasonable, but incompletely substantiated
assumption that intermediate phenotypes in schizophre-
nia are more likely to be modeled by a less complex
genetic architecture than the disorder as a whole.Figure 1
displays a simplified scheme of this concept.
The above statement “less complex genetic architecture
than the disorder as a whole,”does not imply “simple”;an
intermediate phenotype could conceivably be more genet-
ically complex than its parent disorder.However,in the
context of this discussion, we will refer to intermediate
phenotypes as having a less complex relationship to sus-
ceptibility genes than the diagnostic phenotype.The proof
of this assumption rests on the demonstration that genetic
association is statistically stronger for the intermediate
phenotype than for the clinical phenotype.Importantly,
the precise means by which a concentration of intermedi-
ate phenotypes might explain the clinical presentation of
schizophrenia is yet to be determined.Hence,it is also con-
ceivable that schizophrenia is more than a simple sum of
distinct traits.In this view,phenotypic expression of the dis-
order requires the complex interaction of genetic and epi-
genetic matrices and,to some extent,the influence of envi-
ronmental factors,acting perhaps through a final common
pathway.
10,14We will briefly consider evidence to support
the concept of perturbed synaptic architecture as a puta-
tive final common pathway in schizophrenia,and present
recent evidence in support of abnormal cortical informa-
tion processing as the principle clinical feature of the dis-
order conceivably arising as an emergent property of the
synaptic changes.Figure 2 is a schematic representation of
this idea.
Selected abbreviations and acronyms
DLPFC dorsolateral prefrontal cortex
DZ dizygotic (twin)
ERP event-related potential
MZ monozygotic (twin)
NAA N-acetylaspartate
SNP single nucleotide polymorphism
Figure 1. A schematic illustration of the assumption that individual traits are
controlled by fewer risk alleles than the disorder taken as a whole.
This scheme is the principal experimental design incorporated by
the majority of studies discussed in this review. It strongly supports
trait identification as the means of identifying risk alleles.
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Attractive candidates and 
alluring alleles: caveats
Finding evidence of an association between variant alle-
les and a plausible intermediate phenotype depends on
determining whether the allele is statistically associated
with variance in behavioral or biological measures,eg,
scores on cognitive measures.Ideally,a functional vari-
ant with well-described effects at the micro- or macro-
scale should be tested against a well-characterized inter-
mediate phenotype of significant heritability.Absence of
evidence to support a variant’s impact on brain function
should engender caution in the acceptance of purely sta-
tistical evidence of clinical association at the level of diag-
nosis.Even if allelic association with a candidate inter-
mediate phenotype is found, it does not mean that the
allele is necessarily the causative genetic factor.
15,16There
are other possibilities. For example, an unrecognized
allele may be in “linkage disequilibrium”with the tested
allele,thus serving as a “proxy”for the causative factor;
or the association may be an artifact,due to experimen-
tal, statistical, or population stratification errors.
Population stratification signifies genetic population (eth-
nic group) differences in allelic frequency caused by dif-
ferences in their origins and geographic separation.For
example,if members of two genetically diverse groups
score differently on a cognitive measure because of social
or cultural factors,the cognitive differences can be mis-
interpreted as being due to genetic factors.
Defining relative risk: testing the heritability
of an intermediate phenotype
Phenotype reflects the expression of genetic variation.
Association implies that a specific genetic variant is
related to the phenotype and,thus,the phenotype (here
intermediate phenotype) is reasonably heritable, ie,
shows greater prevalence in unaffected relatives of
patients than in the general population.This concept is a
measure of the proportion of healthy siblings displaying
the phenotype relative to the proportion of healthy con-
trols with evidence of the phenotype,and is referred to
as relative risk (RR or lambda).Relative risk computa-
tions based on degree of impairment,ie,one or two stan-
dard deviations (SDs) below control mean,provide evi-
dence that impairment per se is familial and most likely
heritable,and permit the determination of the upper lim-
its of heritability,but are unable to determine the role of
Figure 2. Cognitive information processing in the brain, and the illness denoted as “schizophrenia” is cartooned as an emergent property of the
holistic interactions of gene matrices > synaptic functions > cognition. The normally occurring products of the putative susceptibility genes
discussed in the text are shown to be critically important to aspects of synaptic integrity, plasticity, signal integration, and transmission,
the emergent phenomenon of which, in sum, is cognition and, in this case, psychiatric illness. In one sense, this hypothetical construct
is analogous to a view of a musical symphony as an emergent property of the dynamic interactions of the musical score, the musicians,
instruments, and symphonic conductor. 
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shared environmental factors.Even so,studies of family
aggregations of schizophrenia provide evidence that
shared environmental factors do not play a major role in
schizophrenia; in turn, this implies that environmental
susceptibility factors are specifically experienced only by
the proband.
16,17
Hence, an indispensable first step in the determination
of heritability is a careful match of unaffected siblings
with healthy controls for age,education,gender,IQ,the
absence of diagnosable psychiatric illness, substance
abuse,and medical conditions that impair cognitive per-
formance, such as cardiovascular, endocrine, neuropsy-
chiatric, or metabolic disorders. Fulfillment of these
requirements permits a more accurate computation of
relative risk on other measures of brain function. It is
well recognized that the unaffected sibling of a discor-
dant monozygotic (MZ) twin pair is at the highest pos-
sible risk for schizophrenia in comparison to any other
class of sibling; thus, for example, comparison of cogni-
tion in such individuals with healthy MZ twins should
conceivably yield the highest probability of identifying
putative cognitive intermediate phenotypes in schizo-
phrenia.
18 In particular,if the measured performance of
the unaffected twin falls between affected siblings and
healthy controls, the measure may be a plausible inter-
mediate phenotype.
Intermediate phenotypes in somatic 
disorders: hereditary hematochromatosis
The study of intermediate phenotypes has been espe-
cially productive in a number of common medical con-
ditions,such as coronary heart disease,
19 hypertension,
20
and type 2 diabetes mellitus,
21,22 which are similar to psy-
chiatric disorders in the sense that they arise from a poly-
genic matrix each of which conveys a relatively small
increment of risk. In diabetes, for example,
21,22 insulin-
receptor resistance has been viewed as intermediate
between several susceptibility genes and clinical diabetes;
colon polyps are intermediate phenotypes related to
colon cancer.Studies of genetic susceptibility in heredi-
tary hemochromatosis (HH),a clinical disorder of iron
metabolism,are good examples of the intermediate phe-
notype and the gene of susceptibility concepts.
23-26A sim-
ple,robust,and quantitative measure of serum transfer-
rin saturation was first identified as an intermediate
phenotype in HH.
23,24This led to the recognition of the
high prevalence of hemachromatosis gene (HFE) muta-
tion carriers.
25 The protein encoded by this gene is a
membrane protein that associates with β2-microglobulin
and most likely functions to regulate iron absorption by
regulating the interaction of the transferrin receptor with
transferrin.As one would expect in a complex genetic
disorder,subsequent investigations demonstrated a low
prevalence of clinical pathophysiology in carriers of vari-
ant alleles of the HFE gene,despite high transferrin sat-
uration levels.
25,26The HFE gene is thus recognized as a
susceptibility gene in HH,possibly necessary,but insuf-
ficient,for expression of clinical hemochromatosis.This
illustrates the principle that there are more unaffected
carriers of susceptibility gene variant alleles than persons
with the disorder. It is reasonable to expect insights
gained from the study of somatic disorders will draw
attention to promising molecular targets for effective
therapeutic intervention in schizophrenia.
Cognitive impairment: 
a core feature of schizophrenia
Schizophrenia has been recognized clinically as a disor-
der of cognition since at least 1893,when Emil Kraepelin
referred to this illness as “dementia praecox,”a chronic,
disabling disorder whose core feature was “a disorder of
the will,” or an impairment of executive functions and
working memory in current terminology.Recent clinical
studies confirm the role of cognition in the disability of
this disorder. For example, McGurk and colleagues
27-29
studied the relationship of neuropsychological measures
of executive function and psychiatric symptoms to work
outcomes in 30 patients enrolled in a supported employ-
ment program. Surprisingly, over a 2-year period,
patients’ work outcomes were more strongly predicted
by levels of function in three key domains of cognitive
function than by the severity of their psychotic symp-
toms;the greater the perturbation of working memory,
attentional capacity,and processing speed,the less likely
a patient was to remain employed.Similarly,Bryson and
Bell
30 studied the influence of cognitive function on work
performance in 96 outpatients and found that measures
of attention and verbal working memory were the
strongest predictors of work performance for the first 13
weeks,and measures of verbal working memory were the
strongest predictors of continued employment over the
second 13 weeks. Goldberg and colleagues
18 identified
specific cognitive measures of genetic risk in schizophre-
nia,describing large differences in cognitive performanceIntermediate phenotypes in schizophrenia - Preston and Weinberger Dialogues in Clinical Neuroscience - Vol 7 . No.2 . 2005
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as a whole between unaffected and affected members of
discordant MZ twin pairs,and lesser differences in com-
parisons between the unaffected discordant twins and
controls.Weickert and colleagues
31 studied the pattern of
cognitive decline in a large sample of patients with schiz-
ophrenia and found that 51% experienced a 10-point or
greater decline in IQ from premorbid status, while
another 35% had cognitive deficits from early in life.In
concert with these findings,Cannon et al
32 studied heri-
tability of several domains of cognitive impairment in a
sample of MZ and dizygotic (DZ) twins discordant for
schizophrenia,each compared with healthy control twins.
Using a 17-item battery of neuropsychological tests,they
identified four independently inheritable domains of cog-
nition and demonstrated that abnormalities of working
memory were genetically related to risk for schizophre-
nia.Such studies have attracted increasing attention to
the critical nexus of perturbed cognition,variant geno-
types,and inherited susceptibility to schizophrenia.
Candidate intermediate phenotypes in 
schizophrenia: cognition
Goldberg and colleagues
33 studied cognitive phenotypes
in MZ twins discordant for schizophrenia in comparison
with MZ twins,both of which were healthy.They found
significant differences between the group of unaffected
twins of patients and the healthy twin pairs on tests of
attention,vigilance,and psychomotor speed.The differ-
ence remained even when 10 unaffected twins of a
proband were omitted from analysis because they were
diagnosed with an Axis I or II disorder.As predicted,the
performance of the unaffected twin fell between the
affected and control subjects, but failed to match the
severity found for the affected twin control comparison.
The authors concluded that a lack of equivalent differ-
ences in the comparison of cognitive measures between
the discordant twins and the healthy controls indicated
that the affected discordant twin sustained an environ-
mental insult that additionally impaired cognitive per-
formance.Cannon et al
32 studied heritability of impaired
cognitive performance by determining whether such
deficits covary with the degree of genetic relationship by
comparing scores on a comprehensive neuropsychologi-
cal test battery of twin pairs discordant for schizophrenia
with a well-matched sample of control twin pairs.They
found tests of spatial working memory (ie,remembering
a sequence of spatial locations over a brief delay),
divided attention (ie, simultaneous performance of a
counting and visual-search task),intrusions during recall
of a word list (ie,falsely “remembering”nonlist items),
and choice reaction time to visual targets contributed
uniquely to distinguishing the degree of genetic loading
for schizophrenia.When combined, scores were more
highly correlated within MZ pairs than within DZ pairs,
in both discordant and control twins.The authors sug-
gested that their findings supported the assumption of
multiple independently inherited dimensions of cognitive
deficit in schizophrenia.Interestingly,patients were more
impaired than their MZ cotwin on tests of verbal and
visual episodic memory,suggesting a preferential impact
of nongenetic influences on long-term memory systems.
Egan and colleagues
34,35 estimated the relative risk of
impaired attention as a candidate intermediate phenotype
in schizophrenia,and used the continuous performance
test (CPT), 1-9 version, with and without a distraction
condition,to study 147 patients with schizophrenia,193 of
their siblings,and 47 normal comparison subjects.Relative
risk was estimated by using cutoff scores that were 1,2,
and 3 SDs below the mean of the normal comparison
group in CPT both with and without distraction.Fifty per-
cent of the patients,24% of their siblings,and 18% of the
normal comparison subjects scored 1 SD below the mean
score of the comparison group for the more difficult dis-
traction version of the CPT.The patients with CPT scores
1 SD below the mean score of the comparison group had
a total of 97 siblings. Compared with the comparison
group, this subgroup of siblings had significantly lower
CPT scores.Relative risk was also significantly higher for
the siblings of patients whose scores were 1 SD (RR=2.1)
and 2 SDs (RR=3.3) below the mean of comparison sub-
jects.The authors concluded that poor performance on
the CPT is familial,possibly genetic,and could increase
the power of genetic studies of schizophrenia.
Although perturbations of executive functions seem to
be the most consistently observed candidate intermedi-
ate phenotypes in schizophrenia,given the diversity of
the human cognitive behavioral repertoire, and the
apparent complexity of the molecular genetics subserv-
ing this complex behavioral array,it is unreasonable to
expect any family-based study to mirror a single set of
cognitive or physiological deficits.
35-45 Nonetheless,taken
as a whole, the weight of neuropsychological studies
robustly support assumptions that independent domains
of cognitive function are heritable and are differentially
linked to risk for schizophrenia.Neuroimaging
Structural imaging
Structural imaging protocols have long attracted atten-
tion in schizophrenia research,inasmuch as they are non-
invasive and are a relatively easy means by which to col-
lect large numbers of volunteers. The 1976 study of
Johnstone and colleagues
46 established a relationship
between cerebral ventricular volume and cognitive
impairment in schizophrenia.Using x-ray computerized
tomography, Weinberger et al
47 subsequently found
increased ventricular volume in 12 healthy siblings of
patients with schizophrenia compared with well-matched
healthy controls,and found that the affected siblings had
larger ventricles than their unaffected sibs or healthy
controls;a trend towards larger ventricles was also found
in the unaffected siblings, suggesting a relationship to
state and trait aspects.Reveley and colleagues
48 studied
ventricular size in healthy MZ and DZ twins compared
with MZ twins discordant for schizophrenia. They
reported that ventricular size was highly heritable in
healthy MZ twins (h
2=0.98),moderately heritable in DZ
twins (h
2=0.45),and highly heritable in MZ twins discor-
dant for schizophrenia (h
2=0.87).The results of this study
suggested a strong relationship between family history of
psychosis and lateral ventriculomegaly,but the effect of
shared environmental factors could not be excluded.
Investigators in this field have recently looked at a differ-
ential effect on gray and white matter volumes in the brains
of discordant MZ and DZ twins. Hulshoff Pol and col-
leagues
49 studied whole brain tissue volumes in schizo-
phrenia,intending to determine whether genetic and envi-
ronmental risk factors are differentially reflected in changes
of gray or white matter volume.They used magnetic reso-
nance imaging (MRI) scans to compare 11 MZ and 11
same-gender DZ twin pairs discordant for schizophrenia
with 11 MZ and 11 same-gender DZ healthy control twin
pairs.Repeated-measures analysis of covariance revealed
decreased whole brain volume in the patients with schiz-
ophrenia as compared with their cotwins and with healthy
twin pairs.Decreased white matter volume was found in
probands and unaffected twin siblings compared with
healthy twin control pairs,particularly in the MZ twin pairs.
A decrease in gray matter was found in the patients com-
pared with their discordant cotwins and compared with
healthy twins.The authors suggested that their results indi-
cate that decreases in white matter volume reflect an
increased genetic risk to develop schizophrenia,whereas
the decreases in gray matter volume are related to envi-
ronmental risk factors.This initial study provides intriguing
data suggesting that there are differential genetic effects on
gray and white matter volumes.Further investigations will
need to include nontwin siblings,as it is unclear whether
twinship per se is associated with discrepant headsizes.
50,51
Magnetic resonance spectroscopic imaging
Congruent with structural MRI studies, magnetic reso-
nance spectroscopic imaging (MRSI) studies have that
found levels of cerebral metabolites reflect the activity of
identical brain regions. For instance, Bertolino and col-
leagues
52,53 used single-voxel proton magnetic resonance
spectroscopy (
1H-MRS) to study 10 patients with schizo-
phrenia and 10 controls for evidence of reduced concen-
trations of N-acetylaspartate (NAA),choline-containing
compounds (CHO),and creatine/phosphocreatine (CRE),
which are metabolites considered to be in vivo signals of
neuronal activity,in several brain regions,including dorso-
lateral prefrontal cortex (DLPFC) and hippocampus.They
found that in comparison to controls,patients exhibited sig-
nificantly diminished levels of NAA/CRE and NAA/CHO
in the hippocampus and DLPFC. In a study aimed to
determine whether metabolic measures were a plausible
intermediate phenotype,Callicott et al
54 studied levels of
NAA in the hippocampus and DLPFC of 47 patients with
schizophrenia,60 unaffected siblings,and 66 healthy con-
trol subjects,measuring NAA,CRE,and CHO.They found
that patients and their unaffected siblings had significant
reductions in NAA/CRE hippocampal area compared
with controls. Qualitatively defined “low hippocampal
NAA/CRE phenotypes”yielded relative risk estimates of
between 3.8 and 8.8,suggesting that this characteristic is
heritable.These findings,together with the structural imag-
ing and cognitive studies discussed previously,lend support
to the concept of a strong association between perturba-
tions of structure,metabolism,and cognitive function in
schizophrenia.They also suggest that MRSI-derived mea-
sures of neuronal metabolism represent a novel biological
phenotype for genetic studies of schizophrenia.
Functional magnetic resonance imaging
Functional magnetic resonance imaging (fMRI) is a ver-
satile tool in the search for functional deficits in schizo-
phrenia,and will most likely be seen as a paradigm shift in
Clinical research
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collection of individual,rather than group-averaged,func-
tional neuroimaging data.Even so,a consensus regarding
the interpretation of reported findings remains an unful-
filled goal,in spite of the increasing sophistication of this
technology.
55,56 Callicott
56 and colleagues studied working
memory–related cortical physiology in nonschizophrenic,
cognitively intact siblings of patients with schizophrenia
with fMRI during performance of the N-back working
memory task.They compared 23 unaffected siblings of
schizophrenic patients to 18 matched comparison subjects.
As a planned replication,they studied another 25 unaf-
fected siblings and 15 comparison subjects.In both cohorts,
there were no group differences in working memory per-
formance.Nevertheless,both groups of siblings showed an
exaggerated physiological response in the right DLPFC,
which was qualitatively similar to results of fMRI studies
of patients with schizophrenia.They concluded that inef-
ficient memory processing in the DLPFC,similar to find-
ings in patients with schizophrenia,was associated with
genetic risk for schizophrenia.However,similar studies
have found that patients’ performance is reflected in lesser
activation of right-sided DLPFC,
57,58 while others
59 have
found agreement with the results of Callicott et al.
56
A plausible explanation for this seeming contradiction has
been offered
15 in a study of working memory in which the
authors used the N-back task and 3-tesla fMRI to exam-
ine a group of 14 patients with schizophrenia and a
matched comparison group of 14 healthy subjects.While
all patients’ performance was significantly worse on the 2-
back working memory task than that of healthy subjects,
there were patients with hypoactivated and hyperactivated
areas of DLPFC.Subdivision of the patients into high- and
low-performing groups exposed areas of greater and lesser
prefrontal activation in the high-performing patients,but
only underactivated areas in the low-performing patients.
These findings suggest that patients with schizophrenia
whose performance is similar to that of healthy subjects
use greater prefrontal resources,but achieve lower accu-
racy (ie,inefficiency),while those who fail to sustain a pre-
frontal information signal-processing network achieve
even lower accuracy.In the light of current understanding
of complex disorders,it is not surprising to encounter what,
at first glance,seems to be an example of endophenotypic
heterogeneity,but in regards to identifying genes of risk in
schizophrenia,there is strong agreement that information-
processing mediated by the DLPFC is significantly com-
promised.
Event-related potentials
P50 auditory ERPs
The majority of evidence in support of electrophysiolog-
ical candidate intermediate phenotypes in schizophrenia
derives from studies of event-related potentials (ERPs),
particularly components of P50 auditory ERPs.
60-72 Most
studies of ERPs in schizophrenia are designed to deter-
mine aspects of waveform amplitude or latency that dis-
tinguish healthy controls from patients and their unaf-
fected siblings. P50 studies, however, are typically
composed of a series of trials in which paired click stim-
uli (S1, S2) are presented with a 500-ms interstimulus
interval and a 8- to 10-s intertrial interval,to an alert sub-
ject.The role of the P50 as a candidate intermediate phe-
notype is principally based on group differences in the
ratio S2/S1, or the P50 ratio.
60-65 Similar findings have
been reported for the ratio S2/S1 in the N100 ERP.
64,65
Variance between groups in the P50 auditory ERPs has
been conceived as reflecting perturbed inhibitory factors,
on the basis of the recognition that the amplitude of spe-
cific components of a sensory ERP in healthy subjects
declines with repeated stimulation,depending upon the
interstimulus interval and the refractory period of neural
generators.As a result, it has been proposed that dys-
modulated sensory signals are permitted access to higher-
order cortical processing,an assumption for which direct
evidence is lacking.
60-63
On the basis of evidence that patients with schizophrenia
and their unaffected siblings had a larger P50 ratio than
healthy comparison groups, previous studies of the P50
found support for this ERP as a plausible candidate inter-
mediate phenotype in schizophrenia.For example,on the
Pacific island nation of Palau,Myles-Worsley
63,69 examined
P50 sensory gating in 85 schizophrenia patients (56 med-
icated with typical antipsychotics and 29 unmedicated),83
of their first-degree relatives (46 parents and 37 siblings),
and 29 normal comparison subjects.Abnormal P50 ratios
were found in 64.7% of the schizophrenia patients and
51.8% of their first-degree relatives,but only 10.3% of the
normal subjects.This proportion of abnormal P50 sensory
gating in relatives versus normal subjects resulted in a risk
ratio of 5.0.A relative risk of this size is unusual in com-
parison with relative risk of ±2 in the majority of studies
of complex disorders,but evidence suggests the prevalence
of schizophrenia in this isolated population may be twice
the incidence reported elsewhere.Recently,Leonard and
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70 found that P50 ratio distinguished schizo-
phrenia patients (P50 ratio >0.5) from healthy controls
(P50 ratio <0.5),and predicted the likelihood of a group
association with variant single nucleotide polymorphisms
(SNPs) in the promoter region of the gene for the α7-nico-
tinic receptor (CHNRA7).In other words,if variant alle-
les were considered as a class,control subjects were more
likely to demonstrate a P50 ratio <0.5,and less likely to
have the variant genotype;the converse was the found in
patients with schizophrenia.First-degree relatives were not
included in this analysis.
Raux
71 and colleagues studied two related α7 genes
(CHRNA7 and CHRNA7-like gene) resulting from a par-
tial duplication (from exon 5 to exon 10) in the human
genome.They described two types of genetic variation (i)
a large deletion resulting in a truncation of the open read-
ing frame;and (ii) a -2 bp deletion in exon 6,which specif-
ically affected the CHRNA7-like gene. Genotyping 70
schizophrenic patients and 77 controls who had had P50
ERP recorded,Raux and colleagues found that carrying
at least one -2 bp deletion of exon 6 did not constitute a
risk factor for schizophrenia;on the contrary,healthy con-
trol subjects were more likely to have the -2 bp deletion of
exon 6 associated with P50 ratio >0.45.The authors of this
study concluded that the -2 bp deletion within the
CHRNA7-like gene is a risk factor for P50 sensory gating
deficit,but not for schizophrenia.In a subsequent study,
72
the same group was unable to replicate the CHNRA7 core
promoter variant findings described by Leonard et al,
70 but
found a -194C CHNRA7 promoter polymorphism that
was also associated with a P50 ratio <0.50 as in the
Leonard et al study,except that this allele was also more
frequent in the control group.The authors suggested that
this was a case where the variant allele rendered a pro-
tective effect against the P50 ratio deficit,and the -194C
polymorphism was in linkage disequilibrium with causal
variants of the deficit.Although the evidence to support a
functional association of CHRNA7 promoter variants with
susceptibility to schizophrenia is weak,it may still be the
case that CHRNA7 modulates inhibitory factors in the P50
ERP and,in similar fashion perhaps,modulation of clini-
cal symptoms in schizophrenia.
P300 oddball ERPs
The P300 oddball ERP is a cognitive electrophysiologi-
cal paradigm elicited within a 250- to 450-ms poststimu-
lus window when a subject detects a low probability tar-
get stimulus. The maximum amplitude of the P300
response is recorded from temporoparietal scalp leads.
A number of laboratories
5,73-79 including ours,
5,77 have
found the P300 left temporoparietal component ampli-
tude distinguishes patients with schizophrenia from
healthy controls.However,whether P300 oddball ampli-
tude is a plausible intermediate phenotype in schizo-
phrenia remains undetermined.
The crux is the question of heritability; the issue is
whether siblings share a putative phenotype;and for this
the evidence is decidedly mixed.For example,in a series
of studies,Turetsky and colleagues
78,79 investigated the
P300 oddball paradigm in patients,siblings,and controls,
and found that a larger frontal, but not a smaller tem-
poroparietal, component amplitude, was heritable, as
only patients had reduced temporoparietal P300 ampli-
tudes relative to controls.They concluded P300 frontal
component variance was a candidate intermediate phe-
notype. In our laboratory, we studied 42 patients with
schizophrenia,62 unaffected siblings,and 34 healthy con-
trol subjects with the P300 oddball intending to deter-
mine whether two-dimensional topographic scalp-distri-
bution of amplitude and latency distinguished groups.
77
We found patient P300 amplitude was decreased relative
to healthy controls over the left parietotemporal area by
as much as 54% to 58%;however,there was no differ-
ence between unaffected siblings and healthy subjects.
P300 latencies were unchanged in both comparisons,call-
ing into doubt the candidacy of the P300 as a plausible
intermediate phenotype in this cohort.
In a subsequent study,
5 we revisited the matter of P300
amplitude and latency as intermediate phenotypes in a
new,larger cohort of 66 schizophrenia patients,115 healthy
siblings of schizophrenic patients,and 89 unrelated con-
trols. In this study, a principal component analysis was
applied on the basis of the notion that P300 abnormalities
in siblings of schizophrenic patients may involve a distrib-
uted network of relatively weak cortical generators,and
because our earlier, smaller study using a topographic
analysis of covariance model did not conclude that P300
localized topography predicts risk for schizophrenia.In
partial agreement with Turetsky and colleagues,
78,79 we
found a smaller temporoparietal,and larger frontal prin-
cipal component distinguished patients and unaffected sib-
lings from controls.In comparing our two studies,we con-
cluded that principal component analysis was better able
to identify signals from multiple weak sources,compared
with topographic analysis,and that to some extent,cohort
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a third cohort is in progress in our laboratory.
Blackwood and Muir
75 studied the P300 in members of a
single large pedigree in which schizophrenia and depres-
sion segregate with a balanced chromosomal translocation
in DISC1 involving the long arm of chromosome 1 and the
short arm of chromosome 11.In members of the family
with the t(1;11) translocation,P300 amplitude was reduced
in carrier relatives compared to relatives with a normal
karyotype,regardless of the presence or absence of psy-
chiatric symptoms.The clinical phenotype associated with
the t(1;11) translocation included schizophrenia,schizoaf-
fective disorder,recurrent major depression,and bipolar
disorder. Hence, there is suggestive evidence that P300
abnormalities are associated with the inheritance of risk
for schizophrenia and affective disorders,but the speci-
ficity of the association remains unclear.These interesting
findings merit efforts to determine whether they are replic-
able in other population samples.
Candidate genes
Converging evidence
10-13,80-88 lends strong support to an
evolving concept of a core phenotype in schizophrenia that
is a reflection of a broad-based perturbation of synaptic
functions subserving cortical microcircuit information pro-
cessing.This is implicit in the cognitive and electrophysio-
logical intermediate phenotype results.
80The majority of
genes thus far identified as likely to confer susceptibility to
schizophrenia impact in diverse ways on the development,
activity,plasticity,and composition of various synaptic com-
ponents,eg,axon terminals,cytoplasmic vesicular transport,
dendritic structure,and function.For example,the authors
of a recent comprehensive review of the molecular origins
of schizophrenia
10 identified 12 “good bet”candidate risk
genes,while readily acknowledging the subjective and most
likely transient nature of their list.Caveats notwithstand-
ing,the authors’ stringent criteria included the following:
• Strength of evidence for association with schizophre-
nia,based on sample size and number of replications in
at least three positive independent studies.
• Linkage to a gene locus associated with schizophrenia,
based on data from two recent meta-analyses.
87,88
• Biological plausibility, based on evidence of altered
function and expression in vivo or in vitro.
89-91
• Evidence of altered expression in schizophrenia brain,
based on measures of mRNA or protein, or relative
expression of isoforms or alleles.
92-102
The following candidate genes were particularly high-
lighted: COMT (22q11); DTNBP1 (6p22); NRG1
(8p12-21); RGS4 (1q21-22); GRM3 (7q21-22); DISC1
(1q42); and G72 (13q32-34). Importantly, with regards 
to discussion of intermediate phenotypes in schizophre-
nia, converging evidence to support the candidacy of 
the nominated genes derives from morphometric,
histopathological, and animal experiment data, impli-
cating hippocampal glutamatergic dysfunction,
91
GABAergic (GABA, γ-aminobutyric acid), and gluta-
matergic abnormalities in the DLPFC,
92-95 frontocortical
dopaminergic inervation,
89,90,96 and signal transmission.
98
From this comes the suggestion that schizophrenia may
be viewed as a disorder associated with broad-based dis-
ruptions of cortical synaptic functions and perturbed
synaptic plasticity on the microcircuit scale
10,81-86,99 and as
disruptions of high-order information processing on the
neural systems scale.
15,80
COMT
Egan and colleagues
89 studied abnormalities of prefrontal
cortical function in schizophrenia associated with the reg-
ulation of prefrontal dopamine,a neurotransmitter that
modulates the response of prefrontal neurons during
working memory. They examined the relationship of a
common functional polymorphism (Val(108/158)Met) in
the catechol-O-methyltransferase (COMT) gene,which
accounts for a fourfold variation in enzyme activity and
dopamine catabolism, with both prefrontally mediated
cognition and prefrontal cortical physiology. In 175
patients with schizophrenia,219 unaffected siblings,and
55 controls,COMT genotype was related in allele dosage
fashion to performance on the Wisconsin Card Sorting
Test of executive cognition and explained 4% of variance
(P=0.001) in frequency of perseverative errors.Consistent
with other evidence,these investigators found the load (0,
1,or 2 met alleles) of the low-activity met allele predicted
enhanced cognitive performance.Finally,in a family-based
association analysis of 104 trios,they found a significant
increase in transmission of the val allele to the schizo-
phrenic offspring.These data suggested that the COMT
val allele impairs prefrontal cognition and physiology,and
thereby slightly increases risk for schizophrenia.
Goldberg et al
90 used a working memory paradigm to
study the effects of genotype on increasing memory load
in a large sample of schizophrenia patients,their healthy
siblings,and controls.As in the study by Egan et al,
89 par-
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locus.Goldberg et al found that high-activity val/val indi-
viduals had the poorest working memory performance,
and that met/met individuals had the best performance.
Siblings and patients with schizophrenia performed sig-
nificantly worse than controls;the allelic effects on per-
formance were similar in both tasks across groups.These
authors concluded that genotype significantly affected
working memory,but not subprocesses related to atten-
tion,load,or delay.They also proposed that their findings
support an additive genetic model in which the effect of
allele load is similar in its effects on dorsal prefrontal cor-
tex working memory regardless of the genetic or envi-
ronmental background in which it is expressed.Taken
together,the study of Egan et al,and that of Goldberg et
al,together with those of other,
100-102 but not all,
103 investi-
gators support a role for an effect of COMT val158met
polymorphism on genetic risk,and a critical role in pre-
frontal cortical function,in families of European descent;
it is unclear as to whether COMT variants play such a role
in other population groups,such as Asians.
RGS4
Prasad and colleagues
92 recently reported that genetic
polymorphisms in RGS4,a gene shown to regulate glu-
tamatergic signaling,were associated with robust volu-
metric differences across genotypes in the DLPFC of a
pooled sample of first-episode,unmedicated schizophre-
nia patients compared with control subjects.Separately
analyzed,the investigators found volumetric differences
within the patient group (n=30),but none in control sub-
ject (n=27).Notably,considering the critical role of the
DLPFC in an array of cognitive domains,the results of
this study suggest that RGS4 polymorphisms contribute
to structural alterations in the DLPFC,and may confer
risk for schizophrenia via a related mechanism,possibly
related to the genetic environment.
GRM3
An example of a recent trend in studies aimed at identi-
fying the genetic risk associated with putative intermedi-
ate phenotypes is represented by a recent large study of
217 patients with schizophrenia,311 unaffected siblings,
362 parents, and 136 controls by Egan and colleagues.
93
These investigators employed an array of complementary
measures, including the N-back fMRI paradigm, MRI
spectroscopy,and postmortem histopathology aimed at
testing for an association with schizophrenia and with
putative intermediate phenotypes to a previously identi-
fied gene candidate,GRM3,and exploring potential mech-
anisms of its effects.GRM3 encodes the mGluR3 receptor,
which modulates synaptic glutamate, dopamine, and
GABA.Evidence of aberrant prefrontal cortical function
associated with disrupted glutamatergic pathways has
been widely reported.
94,96-98,104-108 For instance,investigators
have found reduced expression of the excitatory amino
acid transporter (EAAT2) mRNA of patients with schiz-
ophrenia.
97,104,108 In addition,animal models using mGluR2/3
agonists have been shown to block ketamine-induced cog-
nitive deficits and psychosis-like behavioral abnormali-
ties,
109,110 thus suggesting a possible role for GRM3 in psy-
chotic disorders, such as schizophrenia. GRM3 is also
expressed in astrocytes,where it has been shown to regu-
late expression of EAAT2,also known as the glial gluta-
mate transporter
104,105 which is critically responsible for
reuptake of synaptic glutamate.Together, this evidence
supports a potentially important role for this gene in reg-
ulation of glutamate neurotransmission.
Previous studies have found that GRM3 maps to 7q21.1,
a region that has shown evidence of linkage with schizo-
phrenia in at least one family study.
111 SNPs in exon 3 and
intron 3,17 kb apart,were previously shown to be asso-
ciated with schizophrenia
112,113;in another study,support
for GRM3 association in schizophrenia was strong on an
initial sample,but failed to support association on a repli-
cation sample.
107 Egan et al
93 found that a common GRM3
haplotype was strongly associated with schizophrenia
(P=0.0001);within this haplotype,the A allele of an SNP
in intron 2 was slightly overtransmitted to probands
(P=0.02).Subsequently,these investigators studied the
effects of this SNP on an array of neurobiological traits
related to risk for schizophrenia (ie,putative intermedi-
ate phenotypes),and associated with glutamate neuro-
transmission. For tests of cognition, there was a robust
main effect of genotype associated with performance on
verbal list learning and verbal fluency, each of which
index prefrontal function.The physiological basis of the
GRM3 effect was assessed with the N-back fMRI para-
digm; in this, control subjects homozygous for the risk
allele showed hyperactivation patterns in both prefrontal
and medial temporal (hippocampal) regions,a reflection
of inefficiency relative to the other allele carriers matched
for the same performance score.This pattern has been
observed previously in N-back fMRI studies of DLPFC
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porting its plausibility as a cognitive intermediate phe-
notype related to genetic risk,and illustrating in this study
that the risk allele also plays a role in this distinct pattern
of prefrontal inefficiency in healthy controls.
Subsequently,the investigators used MRI spectroscopy to
measure the effect of SNP 4 on NAA,an indirect measure
of prefrontal glutamate neurotransmission,synaptic abun-
dance, and prefrontal extracellular glutamate. NAA has
been previously shown to be lower in DLPFC and hip-
pocampus in schizophrenia.
53 In this study right and left,
DLPFC NAA was lower in risk allele homozygotes than
other genotypes,as would be expected from the cognitive
and fMRI results.Group-by-genotype interaction was not
significant;even so,there was scant effect of genotype on
NAA in the sibling group.Finally,in postmortem human
prefrontal cortex,risk allele homozygotes had significantly
lower mRNA levels of the glial glutamate transporter
EAAT2.The authors suggest these convergent data reflect
a specific molecular pathway by which GRM3 genotype
may alter glutamate neurotransmission,and thus prefrontal
and hippocampal physiology and cognition, thereby
increasing risk for schizophrenia.Nevertheless,the authors
cautiously point out the weakness of GRM3 effects on
intermediate phenotypes in this study,particularly due to
the multiple statistical testing, which is unavoidable in a
study of such complexity.This study is paradigmatic of the
opportunities and the impediments encountered in a com-
bined multimodal effort to identify genes underlying the
neurobiology of cognitive functions in schizophrenia.
Conclusions
In many respects,it is eminently reasonable to search for
intermediate phenotypes in complex disorders such as
schizophrenia, particularly because the matrix of risk
alleles shaping the clinical phenotype will likely turn out
to be far more complex than might have been expected.
Nevertheless,emerging evidence suggests that,in order
to more finely parse the genetic infrastructure,it will be
necessary to more finely parse and validate the most rel-
evant functional phenotypes.This conjunction of aims
may not be easy to achieve.For example,despite a sub-
stantial literature on eye-tracking dysfunctions in schiz-
ophrenia and unaffected siblings,
1,114,115 and increasingly
precise understanding of the physiology of eye move-
ment, it would seem at first glance difficult to imagine
how therapeutic normalization would improve the psy-
chosocial outcome for patients with schizophrenia. In
essence,that is precisely the reason to identify interme-
diate phenotypes and the genes modulating their func-
tions;we do not have sufficient evidence to predict which
intermediate phenotypes we should ignore.For this rea-
son,it will be important to develop an operational defi-
nition of relevance that assigns primacy to putative phe-
notypes most likely to impact clinical outcome.
The apparently incongruent sensory ERP (P50 and P300)
data appears in part to be due to the inherent sensitivity
of ERP experiments to methodological diferences.
116,117 In
the future,researchers may wish to consider using cog-
nitive ERP,for example,
118 particularly in the context of
a combined multimodal approach,and in view of recent
advances in quantitative methods of electronencephalo-
graphic (EEG) analysis.
119 For example, multimodal
experimental design, as in Egan et al,
93 would permit
incorporation of tests of cognition from separable
domains
120-122 embedded in,for example,EEG or fMRI,
in conjunction with corresponding data from molecular
genetics.This view is supported by early unimodal stud-
ies of the N-back working memory paradigm, which
tended to find well-matched siblings and healthy controls
performed equivalently;addition of fMRI activation data
showed sibling groups use increased neural resources in
doing so.It is conceivable that collecting EEG/magne-
toencephalogram (MEG) data indexing the temporal
evolution of a paradigm such as the N-back would allow
an increased understanding of the role of spectral coher-
ence and stimulus-locked phase synchrony in distin-
guishing group differences in the cognitive process,par-
ticularly in light of a developing consensus on a battery
of cognitive instruments that may reliably distinguish
patients with schizophrenia  from comparison groups.
123,124
Finally,the weight of convergent evidence supports ini-
tial assumptions that intermediate phenotypes indexing
disruptions of cognition would enhance the search for
susceptibility genes in schizophrenia.Such developments
support the continuing search for intermediate pheno-
types,and suggest this will be an increasingly effective
strategy empowering the identification of risk alleles in
schizophrenia. ❏
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Fenotipos intermediarios en la 
esquizofrenia: una revisión selectiva
Los estudios orientados a identificar la susceptibili-
dad genética a la esquizofrenia y otros trastornos
psiquiátricos complejos se enfrentan con diferentes
factores de confusión tales como los criterios clíni-
cos subjetivos, las fenocopias que se dan común-
mente, la significativa variabilidad entre los sujetos
de los rasgos candidatos y la probabilidad de hete-
rogeneidad alélica y de locus que se ha tomado
como evidencia para definir la genética de otros
complejos trastornos cerebrales y somáticos huma-
nos. Además, la investigación orientada a la identi-
ficación de los orígenes moleculares de la esquizo-
frenia también debe abordar la confusa naturaleza
del cerebro humano. A diferencia de órganos con
algunos fenotipos celulares, transcriptomas y pro-
teomas comunes, las neuronas individuales a
menudo son distintas unas de otras en todos estos
aspectos. En esta revisión se presentan trabajos
recientes que afirman tentativamente que los estu-
dios de susceptibilidad genética en trastornos poli-
génicos complejos como la esquizofrenia debieran
ser mejorados mediante la identificación de feno-
tipos intermediarios relacionados con aspectos más
fundamentales del desarrollo y función del cerebro.
El progreso en la identificación de fenotipos inter-
mediarios significativos para la esquizofrenia ha
sido posible gracias al avance de metodologías
recientes en neurociencias cognitivas y neuroimá-
genes, y mediante el empleo de técnicas multimo-
dales combinadas. 
Phénotypes intermédiaires dans la 
schizophrénie : une revue sélective
Les études qui ont pour but d’identifier les gènes
de susceptibilité à la schizophrénie et aux autres
troubles psychiatriques complexes sont confrontées
aux facteurs de confusion que sont les critères sub-
jectifs cliniques, les fréquentes phénocopies, la
variabilité significative intrasujets des caractères
étudiés, et la probabilité de l’hétérogénéité des
locus et des allèles dont on sait qu’elle définit la
génétique d’autres troubles somatiques et céré-
braux complexes chez l’homme. De plus, la
recherche consacrée à l’identification des origines
moléculaires de la schizophrénie doit aussi compo-
ser avec la nature déconcertante du cerveau
humain. Contrairement aux organes pourvus de
peu de phénotypes cellulaires courants, les trans-
criptomes et les protéomes, les neurones individuels
sont souvent distincts les uns des autres  à tous
égards. Dans cet article, nous présentons un travail
récent qui évalue l’hypothèse selon laquelle les
études de susceptibilité génétique dans les troubles
complexes polygéniques comme la schizophrénie,
pourraient être améliorées par l’identification des
phénotypes intermédiaires liés à des aspects plus
fondamentaux de la fonction et du développement
du cerveau. L’avènement de nouvelles méthodes en
neurosciences cognitives et en neuro-imagerie ainsi
que l’utilisation de techniques multimodales com-
binées, ont permis de progresser dans l’identifica-
tion de phénotypes intermédiaires significatifs dans
la schizophrénie.
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